The MET proto‑oncogene encodes a receptor tyrosine kinase (RTK) widely known as c‑MET, mapped to chromosome 7q31. Its only ligand is hepatocyte growth factor (HGF), and ligand binding triggers receptor dimerization, autophosphorylation, and downstream signaling through pathways including PI3K/AKT, RAS/MAPK, and STAT. Physiologically, the HGF/MET axis governs embryogenesis, tissue repair, cell motility, proliferation, and survival. In cancer, dysregulation arises via amplification, activating mutations, rearrangements, or overexpression. Such alterations drive invasion, metastasis, angiogenesis, and therapy resistance across numerous solid tumors, notably non‑small cell lung cancer, gastric, liver, and renal carcinomas. Given its strong oncogenic role, MET is a validated biomarker and key target for precision cancer therapies.